183 related articles for article (PubMed ID: 33369283)
1. Neuronal intermediate filament IgGs in CSF: Autoimmune Axonopathy Biomarkers.
McKeon A; Shelly S; Zivelonghi C; Basal E; Dubey D; Flanagan E; Madhavan AA; Mariotto S; Toledano M; Tracy JA; Zekeridou A; Pittock SJ
Ann Clin Transl Neurol; 2021 Feb; 8(2):425-439. PubMed ID: 33369283
[TBL] [Abstract][Full Text] [Related]
2. Paraneoplastic neuronal intermediate filament autoimmunity.
Basal E; Zalewski N; Kryzer TJ; Hinson SR; Guo Y; Dubey D; Benarroch EE; Lucchinetti CF; Pittock SJ; Lennon VA; McKeon A
Neurology; 2018 Oct; 91(18):e1677-e1689. PubMed ID: 30282771
[TBL] [Abstract][Full Text] [Related]
3. Neuronal intermediate filament paraneoplastic autoimmunity complicating avelumab therapy of Merkel cell carcinoma.
Dinoto A; McKeon A; Vattemi G; Carta S; Ferrari S; Mariotto S
J Neuroimmunol; 2022 Jul; 368():577882. PubMed ID: 35580403
[TBL] [Abstract][Full Text] [Related]
4. Autoimmune gait disturbance accompanying adaptor protein-3B2-IgG.
Honorat JA; Lopez-Chiriboga AS; Kryzer TJ; Komorowski L; Scharf M; Hinson SR; Lennon VA; Pittock SJ; Klein CJ; McKeon A
Neurology; 2019 Sep; 93(10):e954-e963. PubMed ID: 31371564
[TBL] [Abstract][Full Text] [Related]
5. Phosphodiesterase 10A IgG: A novel biomarker of paraneoplastic neurologic autoimmunity.
Zekeridou A; Kryzer T; Guo Y; Hassan A; Lennon V; Lucchinetti CF; Pittock S; McKeon A
Neurology; 2019 Aug; 93(8):e815-e822. PubMed ID: 31315972
[TBL] [Abstract][Full Text] [Related]
6. Glial fibrillary acidic protein immunoglobulin G as biomarker of autoimmune astrocytopathy: Analysis of 102 patients.
Flanagan EP; Hinson SR; Lennon VA; Fang B; Aksamit AJ; Morris PP; Basal E; Honorat JA; Alfugham NB; Linnoila JJ; Weinshenker BG; Pittock SJ; McKeon A
Ann Neurol; 2017 Feb; 81(2):298-309. PubMed ID: 28120349
[TBL] [Abstract][Full Text] [Related]
7. Patients with progressive multiple sclerosis have elevated antibodies to neurofilament subunit.
Silber E; Semra YK; Gregson NA; Sharief MK
Neurology; 2002 May; 58(9):1372-81. PubMed ID: 12011283
[TBL] [Abstract][Full Text] [Related]
8. Neurofilament light as an immune target for pathogenic antibodies.
Puentes F; van der Star BJ; Boomkamp SD; Kipp M; Boon L; Bosca I; Raffel J; Gnanapavan S; van der Valk P; Stephenson J; Barnett SC; Baker D; Amor S
Immunology; 2017 Dec; 152(4):580-588. PubMed ID: 28718500
[TBL] [Abstract][Full Text] [Related]
9. Neurologic autoimmunity and immune checkpoint inhibitors: Autoantibody profiles and outcomes.
Sechi E; Markovic SN; McKeon A; Dubey D; Liewluck T; Lennon VA; Lopez-Chiriboga AS; Klein CJ; Mauermann M; Pittock SJ; Flanagan EP; Zekeridou A
Neurology; 2020 Oct; 95(17):e2442-e2452. PubMed ID: 32796130
[TBL] [Abstract][Full Text] [Related]
10. [Neurofilament protein light in multiple sclerosis].
Zhang Y; Li X; Qiao J
Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(39):2745-9. PubMed ID: 18167263
[TBL] [Abstract][Full Text] [Related]
11. Metabotropic glutamate receptor type 1 autoimmunity: Clinical features and treatment outcomes.
Lopez-Chiriboga AS; Komorowski L; Kümpfel T; Probst C; Hinson SR; Pittock SJ; McKeon A
Neurology; 2016 Mar; 86(11):1009-13. PubMed ID: 26888994
[TBL] [Abstract][Full Text] [Related]
12. Increased frequencies of serum antibodies to neurofilament light in patients with primary chronic progressive multiple sclerosis.
Ehling R; Lutterotti A; Wanschitz J; Khalil M; Gneiss C; Deisenhammer F; Reindl M; Berger T
Mult Scler; 2004 Dec; 10(6):601-6. PubMed ID: 15584481
[TBL] [Abstract][Full Text] [Related]
13. Xefiltin, a new low molecular weight neuronal intermediate filament protein of Xenopus laevis, shares sequence features with goldfish gefiltin and mammalian alpha-internexin and differs in expression from XNIF and NF-L.
Zhao Y; Szaro BG
J Comp Neurol; 1997 Jan; 377(3):351-64. PubMed ID: 8989651
[TBL] [Abstract][Full Text] [Related]
14. Increased expression of multiple neurofilament mRNAs during regeneration of vertebrate central nervous system axons.
Gervasi C; Thyagarajan A; Szaro BG
J Comp Neurol; 2003 Jun; 461(2):262-75. PubMed ID: 12724842
[TBL] [Abstract][Full Text] [Related]
15. Demonstration of natural autoantibodies against the neurofilament protein alpha-internexin in sera of patients with endocrine autoimmunity and healthy individuals.
Rajasalu T; Teesalu K; Janmey PA; Uibo R
Immunol Lett; 2004 Jun; 94(1-2):153-60. PubMed ID: 15234547
[TBL] [Abstract][Full Text] [Related]
16. Detection and characterization of autoantibodies directed against neurofilament proteins in human African trypanosomiasis.
Ayed Z; Brindel I; Bouteille B; Van Meirvenne N; Doua F; Houinato D; Dumas M; Jauberteau MO
Am J Trop Med Hyg; 1997 Jul; 57(1):1-6. PubMed ID: 9242309
[TBL] [Abstract][Full Text] [Related]
17. Glutamate receptor antibodies in neurological diseases: anti-AMPA-GluR3 antibodies, anti-NMDA-NR1 antibodies, anti-NMDA-NR2A/B antibodies, anti-mGluR1 antibodies or anti-mGluR5 antibodies are present in subpopulations of patients with either: epilepsy, encephalitis, cerebellar ataxia, systemic lupus erythematosus (SLE) and neuropsychiatric SLE, Sjogren's syndrome, schizophrenia, mania or stroke. These autoimmune anti-glutamate receptor antibodies can bind neurons in few brain regions, activate glutamate receptors, decrease glutamate receptor's expression, impair glutamate-induced signaling and function, activate blood brain barrier endothelial cells, kill neurons, damage the brain, induce behavioral/psychiatric/cognitive abnormalities and ataxia in animal models, and can be removed or silenced in some patients by immunotherapy.
Levite M
J Neural Transm (Vienna); 2014 Aug; 121(8):1029-75. PubMed ID: 25081016
[TBL] [Abstract][Full Text] [Related]
18. Neurological autoimmunity in patients with non-pulmonary neuroendocrine neoplasms: clinical manifestations and neural autoantibody profiles.
Mangioris G; Halfdanarson TR; Lennon VA; Chang BK; Dubey D; Dyck PJB; Flanagan EP; McKeon A; Mills JR; Pittock SJ; Zekeridou A
Eur J Neurol; 2024 Jun; 31(6):e16273. PubMed ID: 38466015
[TBL] [Abstract][Full Text] [Related]
19. CDR2 and CDR2L line blot performance in PCA-1/anti-Yo paraneoplastic autoimmunity.
Vorasoot N; Scharf M; Miske R; Thakolwiboon S; Dubey D; Mills JR; Pittock SJ; Zekeridou A; Ott A; McKeon A
Front Immunol; 2023; 14():1265797. PubMed ID: 37841252
[TBL] [Abstract][Full Text] [Related]
20. Antibodies to the axolemma-enriched fraction in the cerebrospinal fluid and serum of patients with multiple sclerosis and other neurological diseases.
Rawes JA; Calabrese VP; Khan OA; DeVries GH
Mult Scler; 1997 Dec; 3(6):363-9. PubMed ID: 9493635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
